Cellectar Biosciences announces completion of $7.76 nillion registered direct offering
Cellectar announces the closing of its registered direct offering, priced at-the-market, of 1,954,388 shares of its common stock and 41.0412949 shares of its preferred stock. The preferred stock was offered at $100,000 per share and is immediately convertible into 53,369 shares of common stock. October 12, 2017